SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier .
Denali Therapeutics shares were up nearly 25% in recent Tuesday trading after the company announced a $500 million private placement equity financing and plans to spin out its preclinical small.
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier .
Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven therapeutic product candidates across.